# LIST OF FIGURES

<table>
<thead>
<tr>
<th>Fig.</th>
<th>Description</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Role of ROS in multistage carcinogenesis</td>
<td>20</td>
</tr>
<tr>
<td>2</td>
<td>Ultraviolet absorption spectra of native and modified human DNA.</td>
<td>48</td>
</tr>
<tr>
<td>3</td>
<td>Circular dichroism spectra of native and ROS-human DNA.</td>
<td>49</td>
</tr>
<tr>
<td>4</td>
<td>Thermal melting profile of native and ROS-human DNA</td>
<td>51</td>
</tr>
<tr>
<td>5</td>
<td>Hydroxyapatite column chromatography of (a) native human DNA, (b) heat denatured human DNA and (c) ROS-human DNA.</td>
<td>55</td>
</tr>
<tr>
<td>6</td>
<td>Nuclease S1 sensitivity of native and ROS-human DNA</td>
<td>56</td>
</tr>
<tr>
<td>7</td>
<td>Agarose gel electrophoresis of native and modified human DNA</td>
<td>57</td>
</tr>
<tr>
<td>8</td>
<td>Alkaline sucrose density gradient ultracentrifugation of native and ROS-human DNA.</td>
<td>59</td>
</tr>
<tr>
<td>9</td>
<td>Elution profile of standard individual DNA bases on DEAE Sephadex A-25 column.</td>
<td>61</td>
</tr>
<tr>
<td>10</td>
<td>Elution profile of acid hydrolyzed native human DNA on DEAE Sephadex A-25 column.</td>
<td>62</td>
</tr>
<tr>
<td>11</td>
<td>Elution profile of acid hydrolyzed ROS-human DNA on DEAE Sephadex A-25 column.</td>
<td>63</td>
</tr>
<tr>
<td>12</td>
<td>Direct binding ELISA of anti-ROS-human DNA immune and preimmune sera.</td>
<td>66</td>
</tr>
<tr>
<td>13</td>
<td>Direct binding ELISA of various immune and</td>
<td>67</td>
</tr>
</tbody>
</table>
preimmune sera with their respective immunogens.

**Fig.14.** Inhibition of anti-ROS-human DNA immune and preimmune sera with ROS-human DNA.

**Fig.15.** Elution profile of anti-ROS-human DNA-IgG on Protein A-Sepharose CL-4B column.

**Fig.16.** Direct binding ELISA of anti-ROS-human DNA immune and preimmune IgG with ROS-human DNA.

**Fig.17.** Inhibition of anti-ROS-human DNA-IgG binding to ROS-human DNA by various nucleic acids.

**Fig.18.** Inhibition of anti-ROS-human DNA-IgG binding to ROS-human DNA by various nucleic acids.

**Fig.19.** Inhibition of anti-ROS-human DNA-IgG binding to ROS-human DNA by various synthetic polynucleotides.

**Fig.20.** Inhibition of anti-ROS-human DNA-IgG binding to ROS-human DNA by various macromolecules.

**Fig.21.** Band shift assay of anti-ROS-human DNA-IgG binding to (a) native human DNA and (b) ROS-human DNA.

**Fig.22.** Immunofluorescence study on kidney sections of rabbits immunized with native and ROS-human DNA.

**Fig.23.** Light microscopy of kidney sections of rabbit immunized with native human DNA.

**Fig.24.** Light microscopy of kidney sections of rabbit immunized with native human DNA.

**Fig.25.** Light microscopy of kidney sections of rabbits immunized with native human DNA.

**Fig.26.** Light microscopy of kidney sections of rabbits
immunized with ROS-human DNA.

**Fig.27.** Light microscopy of kidney sections of rabbits immunized with ROS-human DNA.

**Fig.28.** Light microscopy of kidney sections of rabbits immunized with ROS-human DNA.

**Fig.29.** Direct binding ELISA of SLE sera to native calf thymus DNA, native human DNA and ROS-human DNA.

**Fig.30.** Inhibition of SLE anti-DNA autoantibody binding to native human DNA by native and ROS-human DNA.

**Fig.31.** Inhibition of SLE anti-DNA autoantibody binding to native human DNA by native and ROS-human DNA.

**Fig.32.** Inhibition of SLE anti-DNA autoantibody binding to native human DNA by native and ROS-human DNA.

**Fig.33.** Elution profile of SLE IgG on Protein A-Sepharose CL-4B column.

**Fig.34.** Band shift assay of SLE IgG binding to (a) native human DNA and (b) ROS-human DNA.

**Fig.35.** Binding of various cancer sera to native and ROS-human DNA.

**Fig.36.** Detection of antibodies against native and ROS-human DNA in sera of patients with cancer of larynx.

**Fig.37.** Detection of antibodies against native and ROS-human DNA in sera of patients with breast cancer.

**Fig.38.** Detection of antibodies against native and ROS-human DNA in sera of patients with cancer of oral cavity.

**Fig.39.** Detection of antibodies against native and ROS-
human DNA in sera of patients with lung cancer.

Fig. 40. Detection of antibodies against native and ROS-human DNA is sera of patients with liver cancer.

Fig. 41. Detection of antibodies against native and ROS-human DNA in sera of patients with cancer of gastrointestinal tract.

Fig. 42. Detection of antibodies against native and ROS-human DNA in sera of patients with cancer of cervix, penis, bladder, bone and Non-Hodgkin's lymphoma.

Fig. 43. Binding of cancer sera collected before and after radiotherapy, to native and ROS-human DNA.

Fig. 44. Elution profile of cancer IgG on Protein A-Sepharose CL-4B column.

Fig. 45. Band shift assay of cancer IgG binding to native and ROS-human DNA.

Fig. 46. Inhibition of binding of anti-ROS-human DNA-IgG by DNA from lymphocytes of breast cancer patients.

Fig. 47. Inhibition of binding of anti-ROS-human DNA-IgG by DNA from lymphocytes of patients with cancer of head and neck.

Fig. 48. Inhibition of binding of anti-ROS-human DNA-IgG by DNA from lymphocytes of patients with cancer of gall bladder.

Fig. 49. Inhibition of binding of anti-ROS-human DNA-IgG by lymphocytes of patients with cancer of cervix.

Fig. 50. Inhibition of binding of anti-ROS-human DNA-IgG by lymphocytes of normal healthy individuals.